![Elisa Agostinetto: Estradiol levels remain the biomarker of choice](https://oncodaily.com/pub/uploads/2024/01/PDLP6Psh_400x400-e1706480986221.png)
Photo taken from Elisa Agostinetto/LinkedIn
Jan 28, 2024, 18:29
Elisa Agostinetto: Estradiol levels remain the biomarker of choice
Elisa Agostinetto, Clinical Research Fellow at the Institute Jules Bordet, recently shared on X/Twitter:
“Out in npj Journals Breast a nice review on the selection of appropriate biomarkers to monitor the effectiveness of ovarian function suppression with GnRH agonists in ER+.
Estradiol levels remain the biomarker of choice.”
Source: Elisa Agostinetto/X
Aug 31, 2024, 09:41